Petros Pharmaceuticals (PTPI) Business Model - Discounting Cash Flows
Petros Pharmaceuticals, Inc.
PTPI (NASDAQ)

Industry

Drug Manufacturers - Specialty & Generic

Sector

Healthcare

Number of Employees

21
Petros Pharmaceuticals's Business Model

Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a patented topical formulation candidate for the treatment of acute Peyronie's disease. The company markets its line of ED products in the form of vacuum erection device products. Petros Pharmaceuticals, Inc. is based in New York, New York.

About Petros Pharmaceuticals

Website: https://www.petrospharma.com

CEO (Chief Executive Officer): Mr. Fady Boctor M.B.A.

IPO date: 2020-12-02

Contact

Country: US

Address: 1185 Avenue of the Americas

City: New York

State: NY

Phone: 973-242-0005

Zip Code: 10036

Other

CIK: 0001815903

ISIN: US71678J2096

CUSIP: 71678J100

discounting cash flows home logo

Discounting Cash Flows

Are you finding our services helpful? Review us on trustpilot logo Trustpilot
Have a question? Contact us